Advertisement

Life-Sciences-USA.com
The Transatlantic Life Sciences Web Portal
This is a free web portal for the life sciences in North America, Europe and Israel... » read more
- Laverock Therapeutics Expands Seed Funding Round to £13.5m (2023-09-28)
Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M. This investment was led by Ca... - Ginkgo Bioworks & Pfizer: Multi-Target RNA Discovery (2023-09-27)
Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of nov... - Twist Bioscience & IMIDomics Partner to Discover Antibodies (2023-09-27)
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and IMIDomics, Inc., a patient-centric drug discovery and development company focused on Immune-Media... - Biosynth Acquires Synthetic Peptides Producer Pepceuticals (2023-09-25)
The acquisition of multi-kilogram GMP and fill-finish capabilities enables the support of all phases of the product life cycle from discovery to commercialisation Biosynth, a supplier of critical materials to the life science industry, is pleased to announce t... - Valo Health & Novo Nordisk: AI for Cardiometablic Diseases (2023-09-25)
> Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes > Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular d... - Transimmune Secures $5m Investment from Gates Fund (2023-09-20)
> Expansion of existing Bill & Melinda Gates Foundation relationship aims to design mRNA guided therapies that more directly mirror the natural immune system response to antigenic threats. > Combination of “physiologic” dendritic cells with mRNA programming coul... - BenevolentAI Signs Strategic Collaboration with Merck (2023-09-20)
> Collaboration utilises BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates, initially for three targets in oncology, neurology and immunology > BenevolentAI to identify and develop innovative compounds through Hit Identification... - Exscientia: AI Drug Discovery Collaboration with Merck KGaA (2023-09-20)
> Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges > Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three proj... - Rentschler Biopharma Appoints Benedikt von Braunmuehl as CEO (2023-09-19)
> Benedikt von Braunmuehl, a transformational leader with a 30-year track record in the global healthcare industry, is named CEO Rentschler Biopharma SE > Company also announces appointment of Tom Roberts, an entrepreneurial trailblazer with over 20 years of exp... - Scinai Immunotherapeutics Closes $1.33m Direct Offering (2023-09-19)
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, ...
Life-Sciences-USA.com is your doorway to the Transatlantic life sciences!
[LSUS] provides free, up-to-date and structured access to
– News
– Products
– Persons
– Organisations
– Financings
– Collaborations
in the North America, Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSUS] is 100% Made in Germany!
» Start here with the latest News!Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top